Table 3.
Subgroup analyses by molecular markers for overall mortality comparing high to low levels of physical activity
| Events/ N | MET-hours / week ≥ 18 vs MET-hours / week < 18 Hazard ratio † (95% CI) |
P interaction |
|
|---|---|---|---|
| All patients with tumor blocks * | 152/473 | 0.60 (0.41-0.86) | |
| FASN | 0.62 | ||
| Negative | 128/390 | 0.65 (0.44-0.96) | |
| Positive | 18/66 | 0.28 (0.09-0.83) | |
| K-ras | 0.91 | ||
| Wildtype | 83/284 | 0.58 (0.34-0.98) | |
| Mutation | 62/169 | 0.56 (0.31-1.00) | |
| p53 | 0.44 | ||
| Negative | 85/276 | 0.73 (0.45-1.19) | |
| Positive | 65/192 | 0.44 (0.24-0.80) | |
| p21 | 0.76 | ||
| Lost | 112/360 | 0.65 (0.43-1.00) | |
| Expressed | 31/90 | 0.57 (0.24-1.36) | |
| p27 | 0.37 | ||
| Lost | 57/195 | 0.67 (0.36-1.24) | |
| Expressed | 82/251 | 0.56 (0.34-0.93) | |
| PI3KCA | 0.71 | ||
| Wildtype | 106/340 | 0.55 (0.35-0.86) | |
| Mutation | 23/69 | 0.80 (0.31-2.03) | |
Abbreviations: MET = metabolic equivalent hours; N = total number of patients; CI = confidence interval
*
Block cohort represents subjects who had tumor blocks available, post diagnosis physical activity data
†
Adjusted for age, gender, stage, year of diagnosis, histology grade, body mass index, time of physical activity assessment